4,460 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Purchased by Andrew Hill Investment Advisors Inc.

Andrew Hill Investment Advisors Inc. bought a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,460 shares of the medical equipment provider’s stock, valued at approximately $1,505,000. Intuitive Surgical accounts for 1.6% of Andrew Hill Investment Advisors Inc.’s holdings, making the stock its 28th largest holding.

Other hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new position in Intuitive Surgical during the 4th quarter valued at $915,360,000. WCM Investment Management LLC bought a new stake in shares of Intuitive Surgical during the fourth quarter worth $575,536,000. Morgan Stanley boosted its stake in shares of Intuitive Surgical by 29.9% during the fourth quarter. Morgan Stanley now owns 5,866,613 shares of the medical equipment provider’s stock valued at $1,556,706,000 after purchasing an additional 1,351,002 shares during the period. Barclays PLC increased its stake in Intuitive Surgical by 159.5% in the 2nd quarter. Barclays PLC now owns 1,379,246 shares of the medical equipment provider’s stock worth $471,619,000 after buying an additional 847,651 shares during the period. Finally, International Assets Investment Management LLC lifted its holdings in Intuitive Surgical by 32,360.5% during the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after buying an additional 684,749 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In other news, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $370.20, for a total transaction of $740,400.00. Following the sale, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,373,093.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $370.20, for a total value of $740,400.00. Following the sale, the director now directly owns 25,319 shares of the company’s stock, valued at $9,373,093.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Gary S. Guthart sold 24,325 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the transaction, the chief executive officer now owns 9,425 shares of the company’s stock, valued at $3,544,365.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 248,418 shares of company stock valued at $95,927,097. Company insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Citigroup raised their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Truist Financial lifted their target price on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. Mizuho increased their price target on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research report on Thursday, January 25th. Stifel Nicolaus upped their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Finally, Robert W. Baird reduced their price target on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $378.48.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded down $4.40 during trading hours on Friday, hitting $368.23. 1,902,390 shares of the company were exchanged, compared to its average volume of 1,647,296. The stock has a market capitalization of $130.52 billion, a price-to-earnings ratio of 75.96, a PEG ratio of 5.81 and a beta of 1.36. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76. The company’s 50 day moving average price is $387.27 and its 200-day moving average price is $342.60.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. Intuitive Surgical’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.00 earnings per share. On average, equities analysts predict that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.